Maxim Group resumed coverage on Adamis Pharmaceuticals
$ADMP
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group resumed coverage of Adamis Pharmaceuticals with a rating of Hold
Save time and jump to the most important pieces.
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 Corporate Highlights In May, the Company closed the merger with DMK Pharmaceuticals Corporation (DMK), a private, clinical-stage biotechnology company at the forefront of endorphin-inspired drug design focused on developing novel treatments for opioid use disorder and other neuro-based diseases. Ebrahim Versi, MD, PhD, CEO of DMK, was named CEO of Adamis and Chairman of the Board of Directors. David J. Margu
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $1.35. The common warrants are immediately exercisable at a price of $1.35 per share and expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants were only purchasable together in this offering, but
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit. Each unit consists of one share of common stock (or a prefunded warrant in lieu thereof) and one warrant to purchase one share of common stock. The common warrants will be immediately exercisable at an exercise price of $1.35 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants can only be purchased together in this offering, b
Maxim Group resumed coverage of Adamis Pharmaceuticals with a rating of Hold
4 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)
3 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)
4 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)
Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer
Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company's special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as we
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update. The company's fourth quarter and full year 2022 financial results news release is expected to be available after 1 p.m. PT on March 16, 2023, and on its websi
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today reported financial results for the third quarter of 2022 and provided an update on recent corporate developments. Process Update In October, the Company announced that it had initiated a process to explore a range of strategic and financing alternatives and had retained an investment bank to assist in evaluating certain alternatives focused on maximizing stockholder value. Potential
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from Chief Executive Officer David J. Marguglio. ADAMIS HAS NEW LEADERSHIP COMMITTED TO ENHANCING SHAREHOLDER VALUE YOUR SUPPORT AT THE ANNUAL MEETING IS CRITICAL TO OUR FUTURE SUCCESS July 21, 2022 Dear Fellow Stockholder: Thank you for your ongoing investment in Adamis Pharmaceuticals Corporation ("we," "our," "Adamis" or the "Company"). Like
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Vickie Reed as a new director and member of the company's board of directors. Richard Williams, Chairman of the Board, commented: "We are pleased to welcome Ms. Reed to the Board and look forward to working with her to pursue long-term stockholder value. Her substantial expertise as a healthcare executive in financial leadership roles at several public companies, and extensive background in finance and accounting, combined with her experience as a director of another public life science company, should allow her to have an immediate positive impact as Adamis exec
David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced a leadership transition plan to support its efforts to unlock long-term growth and value creation opportunities: David J. Marguglio, Co-Founder and Chief Business Officer, has been appointed President and Chief Executive Officer, effective immediately. Dennis J. Carlo, Ph.D., has re
8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
SC 13G/A - DMK PHARMACEUTICALS Corp (0000887247) (Subject)
SC 13D/A - DMK PHARMACEUTICALS Corp (0000887247) (Subject)
SC 13G - Adamis Pharmaceuticals Corp (0000887247) (Subject)
On Thursday, 283 companies set new 52-week lows. 52-Week Low Highlights: The largest company by market cap to set a new 52-week low was Pfizer (NYSE:PFE). Blue Star Foods (NASDAQ:BSFC) was the smallest company when considering market cap to set a new 52-week low. Edible Garden AG (NASDAQ:EDBL) made the largest move down on the session, with shares plummeting 34.15% to reach its 52-week low. Almacenes Exito (NYSE:EXTO) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. The following stocks created new 52-week lows on Thursday: Pfizer (NYSE:PFE) shares made a new 52-week low of $34.04 on Thursday. The stock was down 0.74% for the day. Walt Disney
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders. In conjunction with the name change, the company's common stock is expected to trade under the new Nasdaq ticker symbol "DMK" on or about September 8, 2023. The CUSIP number for the common stock, 00547W307, will remain unchanged. "The new DMK Pharmaceuticals is committed to developing groundbreaking and innovative therapies to establish itself as a leader in the treatment of substance abuse i
On Tuesday morning, 164 companies achieved new lows for the year. 52-Week Low Highlights: NextEra Energy (NYSE:NEE) was the largest firm by market cap to set a new 52-week low. SenesTech (NASDAQ:SNES) was the smallest company in terms of market cap to set a new 52-week low. WeWork (NYSE:WE) saw the largest move of the companies, as shares plummetted 3189.55% to hit a new 52-week low. Tarena International (NASDAQ:TEDU)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low. Here is a list of stocks that set new 52-week lows on Tuesday: NextEra Energy (NYSE:NEE) stock dropped to a yearly low on Tuesday of $65.95. Shares traded down 1.0